A message from our friends at Brownstone Research (Sponsor) |
Editor's Note: What if you could claim a stake in what's set to be the biggest IPO ever... starting with just $500? Click here to see the details from former tech executive and angel investor Jeff Brown – the man who picked Bitcoin, Tesla, and Nvidia before they exploded higher. Or read more below. |
|
Dear Reader, |
What if you could shrink your entire wealth journey from decades down to just 24 hours? |
Sounds impossible... |
But click here and I'll show you how Elon Musk is about to make it a reality. |
In short, Elon Musk is predicting this investment could jump 1,000x higher from here. |
That turns $100 into $100,000... |
$500 into half a million dollars... |
And a tiny stake of $1,000 into $1 million. |
If he's right... |
And I believe he is... |
This could be the best investment opportunity of the decade. |
We have so much to look forward to, |
Jeff Brown
Founder & CEO, Brownstone Research |
|
BONUS ARTICLE |
The "Shadow Market" Behind Biotech |
Most biotech investors live in the loud part of the market: |
clinical trial headlines FDA calendar drama binary outcomes "up 40% / down 60%" days
|
But there's a shadow market that behaves differently. |
These companies don't make drugs. |
They don't hire armies of scientists to run Phase 3 trials. |
They just own the economics — a slice of someone else's success — and they get paid when the product sells. |
That's the hook. |
And it's why royalty businesses can feel like a "trap" for people who only know biotech as a casino: |
You're not betting on one drug. |
You're collecting on a portfolio of math. |
|
What "Biotech Royalties" Actually Means |
A royalty business is basically this: |
Fund (or buy) a piece of a drug's future economics Let someone else take the scientific + commercial risk Collect a percentage of sales (or milestones) if it works
|
Royalty Pharma describes itself as the largest buyer of biopharmaceutical royalties, with royalties on 35+ commercial products plus development-stage candidates. |
Ligand describes its model as funding programs in return for economic rights, purchasing royalty rights, and licensing technologies that help partners develop medicines. |
XOMA calls itself a biotech royalty aggregator with 120+ assets, acquiring rights to future milestone and royalty payments tied to partnered candidates. |
That's the shadow market. (continued below…) |
|
|
The Viral Angle: "The Royalty Trap" |
Here's why this theme can go viral with investors: |
You can get paid on drug sales without picking the next biotech lottery ticket. |
But the "trap" is real too: |
royalties are not guaranteed timing can be lumpy a single major product can dominate cash flow valuation can quietly get expensive when everyone discovers the idea at once
|
So let's do the promised Top 3. |
|
The 3 Public "Royalty" Stocks (That Get Paid When Others Sell) |
1) Royalty Pharma (RPRX) — The "Index Fund" of Biopharma Royalties |
What it is:
Royalty Pharma is essentially a capital allocator that buys slices of blockbuster drug cash flows. It frames itself as the largest buyer of biopharma royalties and highlights a portfolio of royalties tied to 35+ commercial products. |
Why investors like it:
It's the closest thing in public markets to a diversified royalty portfolio where the product companies do the hard work. |
What to watch (the Cheap Investor test): |
Is growth coming from new deals or just "running off" mature products? Are they funding new royalties at good prices, or reaching for yield?
|
Royalty Pharma also actively does structured deals (royalty-backed notes, "synthetic royalties," etc.), so it behaves a bit like an alternative asset manager wearing a biotech suit. |
The trap risk:
If capital is too cheap and competition rises, the returns on new royalty purchases can compress. |
|
2) Ligand Pharmaceuticals (LGND) — The "Royalty + Platform Toll Booth" |
What it is:
Ligand's business model is explicitly built around: |
funding development in return for economic rights, buying royalty rights in development/commercial products, and licensing its technologies to partners.
|
It has also guided to meaningful royalty revenue ranges in recent years (management has given specific royalty revenue outlooks in filings/press releases). |
Why investors like it:
It's not just "collect checks." It's also "own picks and shovels" platforms (like Captisol) that get embedded in partner products — which can create recurring economics. |
The trap risk:
This model can look beautifully stable… until a key partner product slows or a milestone doesn't hit on schedule (royalty + milestone timing can be uneven, even if the long-term thesis is intact). (continued below…) |
|
|
3) XOMA Royalty (XOMA) — The "Long-Dated Option Basket" |
What it is:
XOMA calls itself a biotech royalty aggregator with 120+ assets, focusing heavily on acquiring economic rights tied to partnered pre-commercial candidates in exchange for non-dilutive funding. |
Why investors like it:
This is the "venture-style" version of royalties: |
|
The trap risk:
Early-stage royalty baskets can be quiet for long stretches, then pay off in bursts. If you need smooth quarterly narratives, this is not the cleanest ride. |
|
"But you said vaccines…" |
Here's the cleanest real-world illustration of the vaccine royalty/IP dynamic that just hit the tape: |
Arbutus + Genevant vs Moderna: Moderna agreed to pay up to $2.25B to settle a long-running patent dispute tied to lipid nanoparticle (LNP) tech used in its COVID vaccine, including $950M upfront and up to $1.3B contingent. The settlement also eliminates future royalty obligations from Moderna to those parties for LNP on its upcoming vaccines. |
That's not a "classic royalty company" example — but it proves the point: |
There is a layer of biotech where owning the underlying rights can be worth billions even if you never sell a single dose yourself. |
|
Is the "Biotech Royalties" Trade Cheap? |
Here's the Cheap Investor rule: |
Royalties are attractive when: |
the market is paying too much for "story biotech," and you can buy cash-flow durability at a reasonable price
|
Royalties get less attractive when: |
everyone discovers the trade and bids these names up like they're risk-free bonds deal competition compresses returns portfolios become too concentrated in a few therapies
|
So "cheap" isn't the P/E. |
"Cheap" is: how much certainty you're buying per dollar. |
|
Checklist: How to Avoid the Royalty Trap |
Before you fall in love with the idea, check: |
Concentration: top product exposures matter more than the brochure Duration: how long are the cash flows likely to last? Deal discipline: are they buying royalties at sensible returns or chasing? Lumpiness: do you understand milestone timing vs recurring royalties? Rate sensitivity: royalties can trade like long-duration cash flows when rates move
|
|
Bottom Line |
The "Biotech Royalties" trade is real — a shadow market where companies get paid off the math behind other companies' breakthroughs. |
If you want the clean public-market trio to watch: |
RPRX (scaled buyer/allocator) LGND (royalty + platform tolls) XOMA (basket of long-dated royalty/milestone shots)
|
And the Moderna/Arbutus settlement is your headline reminder that owning the rights can be worth billions — even if you never manufacture a product. |
Educational purposes only; not financial advice. |
Tidak ada komentar:
Posting Komentar